Telix Pharmaceuticals (ASX:TLX) has announced that the last patient has been imaged in a phase one clinical study of the company's investigational prostate cancer imaging product TLX591-CDx.
Telix Japanese prostate cancer imaging study completes enrolment
September 9, 2021 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 27 February
February 27, 2026 - - Podcast -
EU backs Australian-led consortium with up to $250m to advance next-generation influenza vaccines
February 26, 2026 - - Latest News -
United front forms across Asia Pacific to change the future of Pulmonary Arterial Hypertension
February 26, 2026 - - Latest News -
There are, in effect, two Pharmaceutical Benefits Schemes operating in Australia today
February 26, 2026 - - Latest News -
Reading the room on reform might mean following the Budget message
February 25, 2026 - - Latest News -
Weight-loss medicines approved in New Zealand, and recommended for funding, but pathway remains unclear
February 25, 2026 - -
Neurizon advances ALS drug program as funding, trials and global partnerships gain momentum
February 25, 2026 - - Australian Biotech

